Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

So Hee Hong, Hanseul Oh, Yong Wook Park, Hye Won Kwak, Eun Young Oh, Hyo Jung Park, Kyung Won Kang, Green Kim, Bon Sang Koo, Eun Ha Hwang, Seung Ho Baek, Hyeong Jun Park, Yu Sun Lee, Yoo Jin Bang, Jae Yong Kim, Seo Hyeon Bae, Su Jeen Lee, Ki Weon Seo, Hak Kim, Taewoo KwonJi Hwan Kim, Seonghwan Lee, Eunsom Kim, Yeonhwa Kim, Jae Hak Park, Sang In Park, Marta Gonçalves, Byung Mook Weon, Haengdueng Jeong, Ki Taek Nam, Kyung Ah Hwang, Jihye Kim, Hun Kim, Sang Myeong Lee, Jung Joo Hong, Jae Hwan Nam

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), various vaccines are being developed, with most vaccine candidates focusing on the viral spike protein. Here, we developed a previously unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the tetanus toxoid epitope P2 (RBD-P2) and tested its efficacy in rodents and nonhuman primates (NHPs). We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. Immunization with N and RBD-P2 (RBDP2/N) + alum increased T cell responses in mice and neutralizing antibody levels in rats compared with those obtained using RBD-P2 + alum. Furthermore, in NHPs, RBD-P2/N + alum induced slightly faster SARS-CoV-2 clearance than that induced by RBD-P2 + alum, albeit without statistical significance. Our study supports further development of RBD-P2 as a vaccine candidate against SARS-CoV-2. Also, it provides insights regarding the use of N in protein-based vaccines against SARS-CoV-2.

Original languageEnglish
Article numbereabg7156
JournalScience Advances
Volume7
Issue number22
DOIs
StatePublished - May 2021

Fingerprint

Dive into the research topics of 'Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates'. Together they form a unique fingerprint.

Cite this